About eom pharmaceutical - IMUC
EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company, which engages in the development of drugs with the potential to transform therapeutic paradigms. Its pipeline includes EOM613 and EOM147. The company was founded by Eli Goldberger and Shalom Z. Hirschman on March 20, 1987 and is headquartered in Montvale, NJ.
IMUC At a Glance
EOM Pharmaceuticals Holdings, Inc.
136 Summit Avenue
Montvale, New Jersey 07645
| Phone | 1-201-351-0605 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -1,892,133.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
IMUC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -9.855 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.022 |
IMUC Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
IMUC Liquidity
| Current Ratio | 0.344 |
| Quick Ratio | 0.344 |
| Cash Ratio | 0.098 |
IMUC Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -473.573 |
| Return on Equity | N/A |
| Return on Total Capital | 1,075.21 |
| Return on Invested Capital | N/A |
IMUC Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -251.098 |
| Total Debt to Total Assets | 113.399 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |